Brainstorm Cell Therapeutics (NASDAQ:BCLI) Releases Earnings Results, Meets Estimates

Brainstorm Cell Therapeutics (NASDAQ:BCLI) posted its quarterly earnings results on Wednesday. The biotechnology company reported ($0.04) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.04), Zacks reports. During the same period in the prior year, the business earned ($0.27) EPS.

Brainstorm Cell Therapeutics Stock Up 2.7 %

Shares of BCLI stock traded up $0.01 during mid-day trading on Thursday, reaching $0.31. 318,646 shares of the company’s stock traded hands, compared to its average volume of 806,977. The company’s 50-day moving average price is $0.36 and its 200-day moving average price is $0.43. The company has a market cap of $21.95 million, a P/E ratio of -0.98 and a beta of 0.37. Brainstorm Cell Therapeutics has a 12 month low of $0.13 and a 12 month high of $1.81.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on BCLI. StockNews.com began coverage on shares of Brainstorm Cell Therapeutics in a research report on Wednesday. They issued a “hold” rating on the stock. Maxim Group raised Brainstorm Cell Therapeutics from a “hold” rating to a “buy” rating and set a $2.00 target price for the company in a research report on Thursday, July 11th.

About Brainstorm Cell Therapeutics

Brainstorm Cell Therapeutics Inc, a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function.